BVS Insider Trading Activity and SEC Form 4 Filings
BVS insider trading summary
Over the past 12 months, insiders at Bioventus Inc. (BVS) reported 2 sales worth $207K by 2 insiders and no open-market purchases on SEC Form 4. Net insider selling was $207K.
Latest BVS insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| Dec 4, 2025 | Guy P Nohra | Director | Sell | $76K (10,000 @ $7.57) |
| Nov 7, 2025 | Michelle McMurry-Heath | Director | Sell | $131K (17,701 @ $7.42) |
| Apr 11, 2025 | Katrina J Church | SVP & Chief Compliance Officer | Sell | $10K (1,283 @ $7.57) |
| Apr 11, 2025 | Anthony D'Adamio | SVP & General Counsel | Sell | $22K (2,958 @ $7.57) |
| Apr 11, 2025 | Mark Leonard Singleton | SVP & CFO | Sell | $29K (3,875 @ $7.57) |
| Mar 24, 2025 | Mark Leonard Singleton | SVP & CFO | Sell | $54K (5,479 @ $9.79) |
| Mar 17, 2025 | Katrina J Church | SVP & Chief Compliance Officer | Sell | $10K (1,018 @ $9.75) |
| Mar 17, 2025 | Anthony D'Adamio | SVP & General Counsel | Sell | $25K (2,615 @ $9.75) |
| Feb 18, 2025 | Anthony D'Adamio | SVP & General Counsel | Sell | $45K (4,380 @ $10.19) |
| Feb 18, 2025 | Mark Leonard Singleton | SVP & CFO | Sell | $66K (6,498 @ $10.19) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.